• PDF / 170,246 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 27 Downloads / 151 Views

DOWNLOAD

REPORT

---

1 S

Macular oedema and acute macular neuroretinopathy: 3 case reports In a retrospective study of 188 patients, 3 women aged 27–65 years were described, who developed macular oedema (2 patients) or acute macular neuroretinopathy (1 patient) during treatment with fingolimod for multiple sclerosis and/or lisdexamfetamine for weight control [routes and frequencies not stated; not all doses stated]. Case 1: A 65-year-old woman had been receiving fingolimod [Gilenya] 0.5mg for multiple sclerosis. After 57 months of fingolimod initiation, she developed macular oedema 2 weeks later of his cataract extraction. She was then treated with unspecified steroids successfully, and she continued fingolimod treatment for multiple sclerosis. Case 2: A 58-year-old woman had been receiving fingolimod [Gilenya] 0.5mg for multiple sclerosis. Initially, at the screening visit, an optical coherence tomography (OCT) showed normal macular contour. After receiving fingolimod for 9 months, an OCT at follow up visit demonstrated fingolimod associated macular oedema in her left eye. Therefore, she was treated with bromfenac, and she continues receiving fingolimod. After that, an OCT after 6 weeks demonstrated the reduction in oedema. Case 3: A 27-year-old woman developed acute macular neuroretinopathy during treatment with fingolimod for multiple sclerosis and lisdexamfetamine for weight control. She had been receiving fingolimod [Gilenya] 0.5mg for multiple sclerosis. After 5 months of fingolimod initiation, she presented with unilateral photopsia and a paracentral scotoma. Her migraines were treated with sumatriptan, and she was receiving lisdexamfetamine to control weight. She denied any recent viral prodrome vaccinations, pregnancy, oral contraceptive pills or international travel. At that time, her visual acuity was 20/20. The dilated fundus examination demonstrated a subtle reddish lesion just superior to the fovea of the right eye consistent with acute macular neuroretinopathy. Thereafter, her visual defect faded and the flashes of light resolved by 5 months after presentation. After that, she remained stable throughout the period noted at a 13 months follow up. Sonne SJ, et al. Incidence of uveitis and macular edema among patients taking fingolimod 0.5 mg for multiple sclerosis. Journal of Ophthalmic Inflammation and Infection 10: 803518223 2020. Available from: URL: http://doi.org/10.1186/s12348-020-00215-1

0114-9954/20/1832-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 28 Nov 2020 No. 1832